Payment overview · 2025
General Payments
$1,415.95
86 reported records · 19 companies
Healthcare provider profile · identity verified
Jessica Schultz, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SUGAR LAND, TX · NPI 1770561912
Verified facts
What the public records show
CMS Open Payments records show Jessica Schultz, M.D. received $1,415.95 in general payments during 2025 across 86 reported records.
EMD Serono, Inc. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Nuplazid, Nurtec Odt, Qulipta, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Qulipta by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vumerity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nurtec Odt by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $228.39 | 16.1% | 12 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $192.18 | 13.6% | 13 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $190.91 | 13.5% | 13 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $177.37 | 12.5% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $160.44 | 11.3% | 8 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $113.30 | 8.0% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $64.40 | 4.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.03 | 3.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.54 | 3.3% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $35.09 | 2.5% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.68 | 2.0% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $18.28 | 1.3% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $18.28 | 1.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.83 | 1.3% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $15.79 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.53 | 1.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $15.11 | 1.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.96 | 1.1% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $14.84 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,415.95 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $192.18 | 13 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $186.31 | 12 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $177.37 | 14 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $141.33 | 7 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $137.99 | 7 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $113.30 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $64.40 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.03 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $48.03 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.54 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $39.69 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $28.68 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 1067 | 302 |
| Memantine Hcl | Memantine Hcl | 947 | 273 |
| Escitalopram Oxalate | Escitalopram Oxalate | 386 | 100 |
| Gabapentin | Gabapentin | 303 | 89 |
| Quetiapine Fumarate | Quetiapine Fumarate | 210 | 62 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 202 | 57 |
| Buspirone Hcl | Buspirone Hcl | 182 | 55 |
| Primidone | Primidone | 178 | 46 |
| Levetiracetam | Levetiracetam | 149 | 38 |
| Memantine Hcl Er | Memantine Hcl | 148 | 33 |
| Trazodone Hcl | Trazodone Hcl | 142 | 58 |
| Baclofen | Baclofen | 137 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 33 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 129 | 35 |
| Divalproex Sodium | Divalproex Sodium | 108 | 35 |
| Topiramate | Topiramate | 91 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 20 |
| Promethazine Hcl | Promethazine Hcl | 81 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 79 | 14 |
| Galantamine Er | Galantamine Hbr | 76 | 18 |
| Mirtazapine | Mirtazapine | 75 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 62 | 11 |
| Pregabalin | Pregabalin | 62 | 21 |
| Galantamine Hbr | Galantamine Hbr | 61 | 23 |
| Alprazolam | Alprazolam | 60 | 17 |
| Carbamazepine | Carbamazepine | 60 | 25 |
| Lamotrigine | Lamotrigine | 59 | 13 |
| Entacapone | Entacapone | 56 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 15 |
| Belsomra | Suvorexant | 52 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | suppressed |
| Austedo | Deutetrabenazine | 51 | suppressed |
| Qulipta | Atogepant | 51 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 50 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 46 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 45 | 11 |
| Rivastigmine | Rivastigmine | 42 | suppressed |
| Lacosamide | Lacosamide | 41 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 38 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Rytary | Carbidopa/Levodopa | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Amantadine | Amantadine Hcl | 32 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 32 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Carbamazepine Er | Carbamazepine | 29 | suppressed |
| Lisinopril | Lisinopril | 29 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 29 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Xcopri | Cenobamate | 27 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 20 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Ingrezza | Valbenazine Tosylate | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ramelteon | Ramelteon | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 17 | suppressed |
| Vumerity | Diroximel Fumarate | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Rasagiline Mesylate | Rasagiline Mesylate | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Nourianz | Istradefylline | 15 | suppressed |
| Omeprazole | Omeprazole | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Teriflunomide | Teriflunomide | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Rufinamide | Rufinamide | 12 | suppressed |
| Soliris | Eculizumab | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Topamax | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,415.95 · 86 records | EMD Serono, Inc. | AMYVID, AUSTEDO XR, BRIUMVI, CREXONT, INBRIJA, INFINITY, INGREZZA, KISUNLA, LEQEMBI, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, PRECIVITYAD2, QULIPTA, REXULTI, Rystiggo, UBRELVY, VUMERITY, VYVGART HYTRULO, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error